|
UNITED STATES |
|||||
|
SECURITIES AND EXCHANGE COMMISSION |
|||||
|
WASHINGTON, D.C. 20549 |
|||||
|
________________________________________ FORM 8-K |
|||||
|
CURRENT REPORT |
|||||
|
PURSUANT TO SECTION 13 OR 15(d) OF THE |
|||||
|
Date of report (Date of earliest event reported): September 5, 2006 |
|||||
|
GENTA INCORPORATED |
|||||
|
________________________________________ |
|||||
|
Delaware |
000-19635 |
33-0326866 |
|||
|
(State or Other Jurisdiction |
(Commission File Number) |
(I.R.S. Employer |
|||
|
200 Connell Drive, Berkeley Heights, NJ |
07922 |
||||
|
(Address of Principal Executive Offices) |
(Zip Code) |
||||
|
(908) 286-9800 |
|||||
|
(Registrant’s telephone number, including area code) |
|||||
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On September 5, 2006, Genta Incorporated, a Delaware corporation (the “Company”), issued a press release announcing that the Food and Drug Administration (FDA) has made public the briefing documents for the Oncology Drug Advisory Committee’s (ODAC) review of the New Drug Application (NDA) for Genasense® (oblimersen sodium) Injection plus chemotherapy for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. The ODAC meeting will discuss the Genasense application on September 6, 2006 beginning at 8:00 a.m. EDT.
A copy of the press release is filed as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release of the Company dated September 5, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENTA INCORPORATED |
||
| By: | /s/ Richard J. Moran | |
| Richard J. Moran Senior Vice President, Chief Financial Officer and Corporate Secretary |
||
Dated: September 5, 2006